Best Peptides for Metabolic Research: AOD-9604, Semaglutide, MOTS-c, and Tirzepatide

Overview

Metabolic research peptides represent one of the most active areas of current peptide science. This article reviews the compounds most commonly studied in the context of metabolic regulation — their mechanisms, published findings, and key distinctions. All compounds discussed are research chemicals; none are approved for human use outside of specific pharmaceutical formulations.

AOD-9604: Lipolytic Fragment of Growth Hormone

AOD-9604 is a synthetic fragment of human growth hormone (hGH), specifically the C-terminal region (amino acids 176–191). It was developed to isolate the lipolytic (fat-burning) activity of hGH without the growth-promoting or diabetogenic effects of the full molecule.

Mechanism

AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat synthesis) through mechanisms that appear to involve beta-3 adrenergic receptors, independent of the IGF-1 pathway [1]. This distinguishes it from full-length hGH, which exerts metabolic effects partly through IGF-1.

Published Research

- Ng et al. (2000) demonstrated that AOD-9604 reduced body fat in obese mice without affecting blood glucose or IGF-1 levels [1] - A 12-week human clinical trial (Heffernan et al., 2001) found modest but statistically significant reductions in body fat in obese subjects at doses of 1mg/day [2] - AOD-9604 completed Phase II clinical trials for obesity but was not advanced to Phase III by Metabolic Pharmaceuticals

MOTS-c: Mitochondrial-Derived Peptide

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide encoded in mitochondrial DNA. It was identified by Lee et al. in 2015 as a regulator of metabolic homeostasis.

Mechanism

MOTS-c activates AMPK (AMP-activated protein kinase), a master regulator of cellular energy balance. It also inhibits the folate cycle and de novo purine synthesis, redirecting metabolic flux toward fatty acid oxidation [3].

Published Research

- Lee et al. (2015) showed that MOTS-c administration reduced obesity and insulin resistance in high-fat diet mice [3] - Reynolds et al. (2021) demonstrated that MOTS-c levels decline with age in humans, and exogenous MOTS-c improved physical performance in aged mice [4] - Current research is investigating MOTS-c's role in exercise adaptation and age-related metabolic decline

GLP-1 Receptor Agonists: Semaglutide and Tirzepatide

GLP-1 (glucagon-like peptide-1) receptor agonists represent the most clinically advanced class of metabolic peptides. Both semaglutide and tirzepatide are FDA-approved pharmaceutical drugs; they are discussed here strictly in the context of their published research mechanisms.

Semaglutide

Semaglutide is a GLP-1 receptor agonist with 94% homology to native GLP-1. It reduces appetite through hypothalamic GLP-1 receptor activation, slows gastric emptying, and improves insulin secretion in a glucose-dependent manner.

The STEP clinical trial program demonstrated 14.9% mean body weight reduction over 68 weeks at 2.4mg/week subcutaneous dosing in adults with obesity [5].

Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first in its class. By activating both the GIP and GLP-1 receptors simultaneously, it produces additive metabolic effects.

The SURMOUNT-1 trial demonstrated 20.9% mean body weight reduction over 72 weeks at 15mg/week in adults with obesity — the largest weight reduction reported in a pharmaceutical obesity trial to date [6].

Comparison Summary

| Compound | Primary Mechanism | Key Research Finding | Regulatory Status | |---|---|---|---| | AOD-9604 | Beta-3 adrenergic lipolysis | Modest fat reduction in Phase II trials | Research compound | | MOTS-c | AMPK activation, mitochondrial regulation | Reduced obesity/insulin resistance in animal models | Research compound | | Semaglutide | GLP-1 receptor agonism | ~15% body weight reduction in STEP trials | FDA-approved (Ozempic/Wegovy) | | Tirzepatide | Dual GIP/GLP-1 agonism | ~21% body weight reduction in SURMOUNT-1 | FDA-approved (Mounjaro/Zepbound) |

References

1. Ng, F.M., et al. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274–278.
2. Heffernan, M., et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 142(12), 5182–5189.
3. Lee, C., et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443–454.
4. Reynolds, J.C., et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 12(1), 470.
5. Wilding, J.P.H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.
6. Jastreboff, A.M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.